Asenapine reduces anxiety-related behaviours in rat conditioned fear stress model

Acta Neuropsychiatrica

Volumn 28, Issue 6, 2016, Pages 327-336

  Ohyama, Masayo ^a   Kondo, Maho ^a   Yamauchi, Miki ^a   Imanishi, Taiichiro ^a   Koyama, Tsukasa ^b  

^a MEIJI SEIKA KAISHA LTD   (Japan)

^b Ohyachi Hospital   (Japan)

Author keywords

anxiety; asenapine; clozapine; conditioned fear stress; olanzapine

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ASENAPINE; BUSPIRONE; CLOZAPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; OLANZAPINE; SEROTONIN; 6-CHLORO-5-METHYL-1-((2-(2-METHYLPYRID-3-YLOXY)PYRID-5-YL)CARBAMOYL)INDOLINE; AMINOPYRIDINE DERIVATIVE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; FUSED HETEROCYCLIC RINGS; INDOLE DERIVATIVE; NEUROLEPTIC AGENT; SEROTONIN AGONIST; SEROTONIN ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; BEHAVIOR ASSESSMENT; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEAR CONDITIONING TEST; HIPPOCAMPUS; IN VIVO STUDY; MALE; NONHUMAN; RAT; SEROTONIN RELEASE; TRANQUILIZING ACTIVITY; ANIMAL; ANXIETY; COMPLICATION; CONDITIONED REFLEX; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; DRUG THERAPY; ELECTRIC SHOCK; ETIOLOGY; FEAR; MENTAL STRESS; METABOLISM; SPRAGUE DAWLEY RAT;

AMINOPYRIDINES; ANIMALS; ANTI-ANXIETY AGENTS; ANTIPSYCHOTIC AGENTS; ANXIETY; BENZODIAZEPINES; BUSPIRONE; CLOZAPINE; CONDITIONING, CLASSICAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; FEAR; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIPPOCAMPUS; INDOLES; MALE; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN RECEPTOR AGONISTS; STRESS, PSYCHOLOGICAL;

EID: 84973883532     PISSN: 09242708     EISSN: 16015215     Source Type: Journal    
DOI: 10.1017/neu.2016.17     Document Type: Article

References (53)

1. TOLLEFSON GD, SANGER TM, BEASLEY CM, TRAN PV. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998;43:803-810.
2. DAVIS JM, CHEN N. The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials. J Clin Psychiatry 2001;62:757-771.
3. TOHEN M, VIETA E, CALABRESE J et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003;60: 1079-1088.
4. STEIN MB, KLINE NA, MATLOFF JL. Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 2002;159: 1777-1779.
5. BARNETT SD, KRAMER ML, CASAT CD, CONNOR KM, DAVIDSON JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol 2002;16: 365-368.
6. KANE JM, MARDER SR, SCHOOLER NR et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 2001;58:965-972.
7. CORBETT R, HARTMAN H, KERMAN LL et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993;45:9-17.
8. FRYE CA, SELIGA AM. Olanzapine's effects to reduce fear and anxiety and enhance social interactions coincide with increased progestin concentrations of ovariectomized rats. Psychoneuroendocrinology 2003;28:657-673.
9. ROGÓZ Z, SKUZA G. Anxiolytic-like effects of olanzapine, risperidone and fluoxetine in the elevated plus-maze test in rats. Pharmacol Rep 2011;63:1547-1552.
10. SZEWCZAK MR, CORBETT R, RUSH DK et al. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J Pharmacol Exp Ther 1995;274: 1404-1413.
11. COWARD DM, IMPERATO A, URWYLER S, WHITE TG. Biochemical and behavioural properties of clozapine. Psychopharmacology (Ber) 1989;99:S6-S12.
12. BYMASTER FP, CALLIGARO DO, FALCONE JF et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996;14:89-96.
13. PEROUTKA SJ. 5-HT receptors: past, present and future. Trends Neurosci 1995;18:68-69.
14. JONES BJ, BLACKBURN TP. The medical benefit of 5-HT research. Pharmacol Biochem Behav 2002;71:555-568.
15. SCHOTTE A, JANSSEN PF, GOMMEREN W et al. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 1996;124:57-73.
16. SHAHID M, WALKER GB, ZORN SH, WONG EH. Asenapine: a novel psychopharmacologic agent with a unique human receptor signature. J Psychopharmacol 2009;23:65-73.
17. GHANBARI R, EL MANSARI M, SHAHID M, BLIER P. Electrophysiological characterization of the effects of asenapine at 5-HT1A, 5-HT2A, α2-adrenergic and D2 receptors in the rat brain. Eur Neuropsychopharmacol 2009;19:177-187.
18. POTKIN SG, COHEN M, PANAGIDES J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68: 1492-1500.
19. SZEGEDI A, ZHAO J, VAN WILLIGENBURG A, NATIONS KR, MACKLE M, PANAGIDES J. Effects of asenapine on depressive symptoms in patients with bipolar I disorder experiencing acute manic or mixed episodes: a post hoc analysis of two 3-week clinical trials. BMC Psychiatry 2011;11:101.
20. SAMALIN L, CHARPEAUD T, LLORCA PM. Asenapine in bipolar I disorder: evidence and place in patient management. Ther Adv Chronic Dis 2013;4:5-14.
21. FANSELOW MS, HELMSTETTER FJ. Conditional analgesia, defensive freezing, and benzodiazepines. Behav Neurosci 1988;102:233-243.
22. INOUE T, TSUCHIYA K, KOYAMA T. Serotonergic activation reduces defensive freezing in the conditioned fear paradigm. Pharmacol Biochem Behav 1996;53:825-831.
23. INOUE T, HASHIMOTO S, TSUCHIYA K, IZUMI T, OHMORI T, KOYAMA T. Effect of citalopram, a selective serotonin reuptake inhibitor, on the acquisition of conditioned freezing. Eur J Pharmacol 1996;311:1-6.
24. RITTENHOUSE PA, BAKKUM EA, O'CONNOR PA, CARNES M, BETHEA CL, VAN DE KAR LD. Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear. Brain Res 1992;580:205-214.
25. LI X, INOUE T, ABEKAWA T et al. 5-HT1A receptor agonist affects fear conditioning through stimulations of the postsynaptic 5-HT1A receptors in the hippocampus and amygdala. Eur J Pharmacol 2006;532:74-80.
26. PIXINOS G, WATSON C. The rat brain in stereotaxic coordinates, 2nd edn. San Diego: Academic Press, 1986.
27. COSTALL B, DOMENEY AM, KELLY ME, NAYLOR RJ, TOMKINS DM. Actions of ORG 5222 as a novel psychotropic agent. Pharmacol Biochem Behav 1990;35:607-615.
28. MARSTON HM, MARTIN FD, PAPP M, GOLD L, WONG EH, SHAHID M. Attenuation of chronic mild stress-induced 'anhedonia' by asenapine is not associated with a 'hedonic' profile in intracranial self-stimulation. J Psychopharmacol 2011;25:1388-1398.
29. FRÅNBERG O, WIKER C, MARCUS MM et al. Asenapine, a novel psychopharmacologic agent: preclinical evidence for clinical effects in schizophrenia. Psychopharmacology (Berl) 2008;196:417-429.
30. ENE HM, KARA NZ, BARAK N, RESHEF BEN-MORDECHAI T, EINAT H. Effects of repeated asenapine in a battery of tests for anxiety-like behaviours in mice. Acta Neuropsychiatr 2015;11:1-7.
31. INOUE T, TSUCHIYA K, KOYAMA T. Effects of typical and atypical antipsychotic drugs on freezing behavior induced by conditioned fear. Pharmacol Biochem Behav 1996;55: 195-201.
32. ISHIDA-TOKUDA K, OHNO Y, SAKAMOTO H et al. Evaluation of perospirone (SM-9018), a novel serotonin-2 and dopamine-2 receptor antagonist, and other antipsychotics in the conditioned fear stress-induced freezing behavior model in rats. Jpn J Pharmacol 1996;72:119-126.
33. MEAD A, LI M, KAPUR S. Clozapine and olanzapine exhibit an intrinsic anxiolytic property in two conditioned fear paradigms: contrast with haloperidol and chlordiazepoxide. Pharmacol Biochem Behav 2008;90:551-562.
34. SUN T, HE W, HU G, LI M. Anxiolytic-like property of risperidone and olanzapine as examined in multiple measures of fear in rats. Pharmacol Biochem Behav 2010;95:298-307.
35. KOŁACZKOWSKI M, MIERZEJEWSKI P, BIENKOWSKI P, WESOŁOWSKA A, NEWMAN-TANCREDI A. Antipsychotic, antidepressant, and cognitive-impairment properties of antipsychotics: rat profile and implications for behavioral and psychological symptoms of dementia. Naunyn Schmiedebergs Arch Pharmacol 2014;387:545-557.
36. BROEKKAMP CL, DE GRAAF JS, VAN DELFT AM. Behavioural pharmacology of trans-5-chloro-2-methyl-2,3,3a,12btetrahydro- 1H-dibenz[2,3:6,7]oxepino-[4,5-c]pyrrolidine maleate, a compound interacting with dopaminergic and serotonergic receptors. Arzneimittelforschung 1990;40: 544-549.
37. ENE HM, KARA NZ, EINAT H. The effects of the atypical antipsychotic asenapine in a strain-specific battery of tests for mania-like behaviors. Behav Pharmacol 2015;26: 331-337.
38. THOMPSON BL, ROSEN JB. Immediate-early gene expression in the central nucleus of the amygdala is not specific for anxiolytic or anxiogenic drugs. Neuropharmacology 2006;50:57-68.
39. WISŁOWSKA-STANEK A, ZIENOWICZ M, LEHNER M et al. Buspirone attenuates conditioned fear-induced c-Fos expression in the rat hippocampus. Neurosci Lett 2005;389:115-120.
40. KAKUI N, YOKOYAMA F, YAMAUCHI M et al. Anxiolytic-like profile of mirtazapine in rat conditioned fear stress model: Functional significance of 5-hydroxytryptamine 1A receptor and alpha1-adrenergic receptor. Pharmacol Biochem Behav 2009;92:393-398.
41. MILLAN MJ. Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies. Therapie 2005;60:441-460.
42. HARVEY ML, SWALLOWS CL, COOPER MA. A double dissociation in the effects of 5-HT2A and 5-HT2C receptors on the acquisition and expression of conditioned defeat in Syrian hamsters. Behav Neurosci 2012;126:530-537.
43. BAGDY G, GRAF M, ANHEUER ZE, MODOS EA, KANTOR S. Anxiety-like effects induced by acute fluoxetine, sertraline or m-CPP treatment are reversed by pretreatment with the 5-HT2C receptor antagonist SB-242084 but not the 5-HT1A receptor antagonist WAY-100635. Int J Neuropsychopharmacol 2001;4:399-408.
44. DEKEYNE A, MANNOURY LA COUR C, GOBERT A et al. S32006, a novel 5-HT2C receptor antagonist displaying broad-based antidepressant and anxiolytic properties in rodent models. Psychopharmacology (Berl) 2008;199:549-568.
45. MASUDA T, NISHIKAWA H, INOUE T et al. 5-HT depletion, but not 5-HT1A antagonist, prevents the anxiolytic-like effect of citalopram in rat contextual conditioned fear stress model. Acta Neuropsychiatr 2013;25:77-84.
46. MARTIN JR, BALLARD TM, HIGGINS GA. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety. Pharmacol Biochem Behav 2002;71:615-625.
47. HUANG M, LI Z, DAI J, SHAHID M, WONG EH, MELTZER HY. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008;33: 2934-2945.
48. KENNETT G, LIGHTOWLER S, TRAIL B, BRIGHT F, BROMIDGE S. Effects of RO60 0175, a 5-HT2C receptor agonist, in three animal models of anxiety. Eur J Pharmacol 2000;387: 197-204.
49. TAKAMURA N, MASUDA T, INOUE T, NAKAGAWA S, KOYAMA T. The effects of the co-administration of the α1-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat. Prog Neuropsychopharmacol Biol Psychiatry 2012;39:107-111.
50. FRÅNBERG O, MARCUS MM, IVANOV V, SCHILSTRÖM B, SHAHID M, SVENSSON TH. Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms. Psychopharmacology (Berl) 2009;204:254-264.
51. ASSIÉ MB, RAVAILHE V, FAUCILLON V, NEWMAN-TANCREDI A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 2005;315:265-272.
52. HEDLUND PB. The 5-HT7 receptor and disorders of the nervous system: an overview. Psychopharmacology (Berl) 2009;206:345-354.
53. WESOŁOWSKA A. Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data. Pharmacol Rep 2010;62:564-577.